Let me guess the next 6 months. Capital raising at higher SP for pipeline expansion and market penetration followed by shorting/pushing it back down to 30 cents.
Having said this, the tech and management plan seem good. Like all other Australian small biotech companies, how does one predict profitablity?
Ann: Becoming a substantial holder, page-7
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add GSS (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
69.0¢ |
Change
0.010(1.47%) |
Mkt cap ! $155.4M | |||
| Open | High | Low | Value | Volume |
| 68.5¢ | 69.0¢ | 68.5¢ | $145.8K | 211.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2851 | 68.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 70.0¢ | 10137 | 1 |
View Market Depth
| Last trade - 15.46pm 28/11/2024 (20 minute delay) ? |
| GSS (ASX) Chart |
